Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Johnson and Johnson
UBS
Mallinckrodt
Express Scripts
Teva
Colorcon
Healthtrust
Cerilliant
Boehringer Ingelheim

Generated: October 18, 2017

DrugPatentWatch Database Preview

Upsher-smith Labs Company Profile

« Back to Dashboard

What is the competitive landscape for UPSHER-SMITH LABS, and when can generic versions of UPSHER-SMITH LABS drugs launch?

UPSHER-SMITH LABS has sixty-eight approved drugs.

There are ten US patents protecting UPSHER-SMITH LABS drugs on UPSHER-SMITH LABS drugs in the past three years.

There are twenty-one patent family members on UPSHER-SMITH LABS drugs in nine countries and thirty-six supplementary protection certificates in eight countries.

Summary for Applicant: Upsher-smith Labs

International Patents:21
US Patents:10
Tradenames:47
Ingredients:42
NDAs:68
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher-smith Labs
NYSTATIN
nystatin
POWDER;TOPICAL065183-001May 3, 2005ATRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-005Mar 11, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
VOGELXO
testosterone
GEL, METERED;TRANSDERMAL204399-003Jun 4, 2014BXRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
FOSINOPRIL SODIUM
fosinopril sodium
TABLET;ORAL076483-002Apr 23, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
MIRTAZAPINE
mirtazapine
TABLET;ORAL076219-003Jun 19, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-005Mar 11, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
MORPHINE SULFATE
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL202104-004Jun 3, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
TOPIRAMATE
topiramate
TABLET;ORAL078499-003Jan 7, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
MORPHINE SULFATE
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL202104-002Jun 3, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
LOSARTAN POTASSIUM
losartan potassium
TABLET;ORAL090544-001Oct 6, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for UPSHER-SMITH LABS drugs

Drugname Dosage Strength Tradename Submissiondate
topiramate
Extended-release Capsules25 mg, 50 mg, 100 mg, 150 mg, and 200 mg
QUDEXY XR
12/24/2015
calcitonin-salmon (recombinant)
Nasal Spray200 IU/spray
FORTICAL
3/29/2006

International Patent Family for Upsher-smith Labs Drugs

Country Document Number Estimated Expiration
Canada2905011► Subscribe
South Korea20150132838► Subscribe
World Intellectual Property Organization (WIPO)2014143380► Subscribe
World Intellectual Property Organization (WIPO)2015089289► Subscribe
Australia783952► Subscribe
Canada2857286► Subscribe
South Korea101674509► Subscribe
China1422160► Subscribe
European Patent Office3079703► Subscribe
European Patent Office1251867► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Upsher-smith Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0030Belgium► SubscribePRODUCT NAME: KALII LOSARTAN, HYDROCHLOROTHIAZIDUM; NAT. REGISTRATION NO/DATE: 922 IS 174 F 3 19980223; FIRST REGISTRATION: FR 338 520.7 19950215
50009Netherlands► SubscribePRODUCT NAME: LOSARTAN, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET KALIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 17617 19950314; FIRST REGISTRATION: SE 12209 19940902
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
00478Netherlands► SubscribePRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
00486Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216
C0026France► SubscribePRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C0048France► SubscribePRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
C/GB99/024United Kingdom► SubscribePRODUCT NAME: N-(3-(3-CYANOPYRAZOLO(1,5-A)PYRIMIDIN-7-YL)PHENYL)-N-ETHYLACETAMIDE (ZALEPLON); REGISTERED: UK EU/1/99/099/001 19990312; UK EU/1/99/099/002 19990312; UK EU/1/99/099/003 19990312; UK EU/1/99/099/004 19990312; UK EU/1/99/099/005 19990312; UK EU/1/99/099/006 19990312; UK EU/1/99/102/001 19990312; UK EU/1/99/102/002 19990312; UK EU/1/99/102/003 19990312; UK EU/1/99/102/004 19990312; UK EU/1/99/102/005 19990312; UK EU/1/99/102/006 19990312
00375Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
Julphar
Cerilliant
McKinsey
Colorcon
Argus Health
Federal Trade Commission
Johnson and Johnson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot